Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck

Open-Label, Multicenter, Phase Ⅱ Study Of Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin As First-Line Treatment In Patients With Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03830385

Enrollment

Registered

2019-02-05

Start date

2019-02-15

Completion date

2026-02-15

Last updated

2019-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous Cell Carcinoma Of The Head And Neck

Brief summary

The purpose of this single arm, phase Ⅱ clinical trail is to determine the safety and efficacy of paclitaxel (albumin bound),bleomycin and cisplatin or carboplatin in the treatment of recurrent Or metastatic squamous cell carcinoma of the head and neck

Interventions

DRUGPaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin

All patients enrolled in the study will accept Paclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin as their firstline chemotherapy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* biopsy proved squamous cell carcinoma of the head and neck; * stage IVc according to Union for International Cancer Control (UICC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy; * 18 years or older; without other malignancy; * proper functioning of the major organs.

Exclusion criteria

* allergic to paclitaxel (albumin bound) or bleomycin or cisplatin or carboplatin ; * female within gestation period or lactation; * patients received drug of other clinical trial within 3 months

Design outcomes

Primary

Measure	Time frame	Description
overall survival	5 years	overall survival

Countries

China

Contacts

Primary ContactQingqing Cai, PhD

caiqq@sysucc.org.cn0086-20-87342823

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026